Oral chelation: Should it be used with young children?

Pediatric Blood and Cancer

Volumn 55, Issue 4, 2010, Pages 603-605

  Mednick, Lauren M ^a   Braunstein, Jennifer ^a   Neufeld, Ellis ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Adherence; Oral chelation; Thalassemia; Young children

Indexed keywords

DEFERASIROX; DEFEROXAMINE; IRON CHELATING AGENT; BENZOIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; CHILD; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HUMAN; IRON CHELATION; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REWARD; THALASSEMIA; PRESCHOOL CHILD;

BENZOIC ACIDS; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; HUMANS; IRON CHELATING AGENTS; MEDICATION ADHERENCE; TRIAZOLES;

EID: 77957099433     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22727     Document Type: Article

References (11)

1. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29: 909-917.
2. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependant thalassemia: A literature review. Transfusion 2007; 47: 1919-1929.
3. Cappellini MD, Cohen A, Piga A, et al. A Phase III Study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalessemia. Blood 2005; 107: 3455-3462.
4. Pontali E, Feasi M, Toscanini F, et al. Adherence to combination antiretroviral treatment in children. HIV Clin Trials 2001; 2: 466-473.
5. Wysocki T, Huxtable K, Linscheid TR, et al. Adjustment to diabetes mellitus in preschoolers and their mothers. Diabetes Care 1989; 12: 524-529.
6. Goode M, McMaugh A, Crisp J, et al. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care 2003; 15: 403-408.
7. Gibb DM, Goodall RL, Giacimet V, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis J 2003; 22: 56-62.
8. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to Chelation therapy in β-thalassemia major. Blood 2008; 111: 583-587.
9. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009; 114: 4009-4013.
10. Anderson GD, Lynn AM. Optimizing pediatric dosing: A developmental pharmacologic approach. Pharmacotherapy 2009; 29: 680-690.
11. Osborne RH, Lourenco RD, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: A time trade-off study. Value Health 2007; 10: 451-456.